Seeing Is Believing
Currently out of the existing stock ratings of Michael King, 107 are a BUY (97.27%), 3 are a HOLD (2.73%).
Analyst Michael King works with a stock forecast success ratio of 38.65% fulfilled within 109.68 days on average. Previously, Michael King worked at HCWAINWRIGHT.
Michael King’s has documented 207 price targets and ratings displayed on 21 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on SONN, Sonnet Biotherapeutics Holdings at 23-Aug-2023.
Analyst best performing recommendations are on NTLA (INTELLIA THERAPEUTICS).
The best stock recommendation documented was for NTLA (INTELLIA THERAPEUTICS) at 6/25/2021. The price target of $111 was fulfilled within 3 days with a profit of $22.17 (24.96%) receiving and performance score of 83.19.
Average potential price target upside
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
234
$79.61 (51.56%)
234
1 days ago
0/3 (0%)
$79.61 (51.56%)
Buy
235
$80.61 (52.21%)
235
1 months 8 days ago
2/14 (14.29%)
$85.31 (56.99%)
149
Buy
227
$72.61 (47.03%)
237
1 months 12 days ago
14/22 (63.64%)
$80 (54.42%)
171
Hold
161
$6.61 (4.28%)
171
1 months 12 days ago
2/2 (100%)
$14 (9.52%)
5
Buy
225
$70.61 (45.73%)
250
1 months 12 days ago
2/6 (33.33%)
$78 (53.06%)
435
What Year was the first public recommendation made by Michael King?